Loading...
| A01658 | Pages: 234 | Jul 2021 | 16488 Views | | |
| Author(s) : Trupti Wadekar, Snehal Manjrekar , Onkar Sumant | Tables: 110 | Charts: 46 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Animal Vaccines Market
Request Now !The global animal vaccines market size was valued at $9,093.9 million in 2020, and is projected to reach $15,201.5 million by 2030, registering a CAGR of 5.2% from 2021 to 2030. Animal vaccines control the transmission of diseases, thus providing protection to animal and human health, which is essential considering the public dependency on animals. Animals serve as an important source of food, meat, milk, protein, and other commercial products such as leather and wool. Most commonly used veterinary vaccines include rabies vaccines, foot & mouth diseases vaccines, and equine influenza virus vaccines, which prevent the transmission of infectious agents by mimicking the naturally acquired immunity. Constant development of vaccines is essential with rise in emergence of different animal diseases. Increase in pet ownership has significantly accelerated the growth of the market.
The animal vaccines market is expected to experience steady growth due to increase in pet ownership in developed countries and rise in number of cattle & poultry in developing countries. Furthermore, surge in investment for R&D of vaccines, which inhibit the growth of antibiotic-resistant organisms boost the growth of the animal vaccines market growth. For instance, in August 2016, Elanco invested two-thirds of the budget for food‐animal unit to develop vaccines and reduce the use of antibiotics. Moreover, rise in demand for animal vaccines has led to the emergence of multiple new vaccines. For instance, Cevac IBron a new vaccine was launched by Ceva in February 2017 that prevents against infectious bronchitis virus (IBV).
Get more information on this report : Request Sample Pages
However, lack of animal health awareness and possibility of adverse impact on veterinary vaccines on human and other animal health restrain the growth of the animal vaccines market. Furthermore, advancements in vaccine products and production of animal vaccines for hybrid animals help open new avenue for the growth of the animal vaccines market.
COVID-19 pandemic has affected the market unfavorably. For instance, after COVID-19 was declared as a pandemic by WHO, countries worldwide adopted nationwide lockdowns to observe social distancing as a measure to contain the spread. This led to disruption, limitation, challenges, and changes in each sector of every industry. Similarly, animal vaccines industry was also impacted by the pandemic. For instance, veterinary organizations across the globe have recommended limiting animal patient care to acutely ill animals and emergencies. Furthermore, the lockdowns have led to rescheduling of annual checkup exams and elective vaccination procedures. However, various key players have ensured the supply of animal vaccines as the governmental institutions across the globe are taking strict measures to maintain the supply to avoid zoonotic viruses from spreading into communities. However, the overall impact of COVID-19 on the animal vaccines market remains fairly negative, owing to fall in demand as veterinary visits are limited, and animal healthcare approach is changed to providing care to emergency cases and critically ill animals.
By product type, the market is categorized into attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, conjugate vaccines, recombinant vaccines, and DNA vaccines. The attenuated vaccines segment dominated the product type segment with maximum share in 2020 in the animal vaccines market size. Attenuated vaccines can provide stronger immunity as compared to other vaccines by activating a wide range of immune response. Moreover, it helps reduce the need for booster vaccines that can be administered via oral route, and induces long-lasting and rapid onset of immunity, which positively contributes toward the growth of the animal vaccines market.
Get more information on this report : Request Sample Pages
By animal type, the global animal vaccines market is segmented into companion animal, livestock animal, and aquaculture. The companion animal segment is further segmented into cats and dogs. The livestock animal segment is further classified into cattle, pigs, poultry, sheep, and others (goats, horses, asses, camel, others). The livestock segment contributed the maximum revenue in 2020 for the growth of the animal vaccines market, attributable to increase in consumption of meat, milk, and dairy products, making sustainable animal health a vital aspect in disease management. However, the companion animal segment is expected to be the fastest growing segment as a large number of these animals are commonly in contact with humans and the infections such as rabies can affect humans too. Moreover, increase in number of adoptions of these companion animals and rise in awareness regarding the importance of vaccines for dogs and cats help to fuel the market growth.
Get more information on this report : Request Sample Pages
By region, the animal vaccines market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest revenue in the global animal vaccines market. This is attributable to high adoption of companion animals, rise in the consumption of meat and milk, and surge in awareness regarding the benefits of using animal vaccines. Asia-Pacific possesses high market potential that could affect the animal vaccines market trends due to increase in pet ownership and rise in incidence of various zoonotic diseases. Moreover, ongoing research on innovative vaccine production technology has increased due to high demand for animal-based food products and companion animals. In addition, increase in investments in animal healthcare companies has improved the production of innovative vaccines.
Get more information on this report : Request Sample Pages
The report provides a comprehensive analysis of the key players operating in the animal vaccines industry. These players include Merck & Co., Inc., Zoetis Inc., Ceva Santé Animale, Sanofi S.A., Romvac, Vaxxinova, Biovac, Merial, Boehringer Ingelheim GmbH and Anicon Labor GmbH. The other players that operate in animal vaccines market include Nexvet, PHL Associates, Inc., Hygieia Biological Laboratories, Colorado Serum Company, Pfizer, and Arko Laboratories, Ltd.
Key Benefits For Stakeholders
Key Market Segments
By Product
By Animal Type
By Region
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits to the stakeholders
1.3.Key market segments
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top winning strategies
3.2.2.Top investment pockets
3.3.Government Regulations
3.3.1.Center for Veterinary Biologics (CVB)
3.4.Top player positioning
3.5.Porter’s five forces analysis
3.6.Market dynamics
3.6.1.Drivers
3.6.1.1.Growth in demand for pet insurance
3.6.1.2.Increase in prevalence of animal diseases
3.6.1.3.Growth in ownership of companion animal
3.6.1.4.Rise in animal health expenditure
3.6.2.Restraints
3.6.2.1.Highly competitive meat and milk prices
3.6.2.2.Adverse impact of veterinary vaccines on human and animal health
3.6.3.Opportunities
3.6.3.1.Advancement in vaccine products
3.6.3.2.Increase in demand for hybrid animal
3.7.COVID-19 Impact Analysis on the market
3.8.mRNA animal vaccine clinical analysis
3.9.Pricing analysis
CHAPTER 4:ANIMAL VACCINES MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Attenuated Vaccines
4.2.1.Key market trends, key growth factors and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Inactivated Vaccines
4.3.1.Key market trends, key growth factors and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Subunit Vaccines
4.4.1.Key market trends, key growth factors and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Toxoid Vaccines
4.5.1.Key market trends, key growth factors and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
4.6.Conjugate Vaccines
4.6.1.Key market trends, key growth factors and opportunities
4.6.2.Market size and forecast
4.6.3.Market analysis, by country
4.7.Recombinant Vaccines
4.7.1.Key market trends, key growth factors and opportunities
4.7.2.Market size and forecast
4.7.3.Market analysis, by country
4.8.DNA Vaccines
4.8.1.Key market trends, key growth factors and opportunities
4.8.2.Market size and forecast
4.8.3.Market analysis, by country
CHAPTER 5:ANIMAL VACCINES MARKET, BY ANIMAL TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Companion animal
5.2.1.Market size and forecast, by type
5.2.1.1.Dogs
5.2.1.1.1.Market size and forecast
5.2.1.1.2. Market size and forecast, by disease
5.2.1.2.Cats
5.2.1.2.1.Market size and forecast
5.2.1.2.2. Market size and forecast, by disease
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.3.Livestock Animal
5.3.1.1.Cattle
5.3.1.1.1.Market size and forecast
5.3.1.1.2. Market size and forecast, by disease
5.3.1.2.Pigs
5.3.1.2.1.Market size and forecast
5.3.1.2.2. Market size and forecast, by disease
5.3.1.3.Poultry
5.3.1.3.1.Market size and forecast
5.3.1.3.2. Market size and forecast, by disease
5.3.1.4.Sheep
5.3.1.4.1.Market size and forecast
5.3.1.4.2. Market size and forecast, by disease
5.3.1.5.Horses
5.3.1.5.1.Market size and forecast
5.3.1.5.2.Market size and forecast, by disease
5.3.1.6.Others
5.3.1.6.1.Market size and forecast
5.3.1.6.2. Market size and forecast, by disease
5.4.Aquaculture
5.4.1.Market size and forecast
5.4.2.Market size and forecast, by disease
5.4.3.Market analysis, by country
CHAPTER 6:ANIMAL VACCINES MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends, key growth factors and opportunities
6.2.2.Market size and forecast, by product
6.2.3.Market size and forecast, by animal type
6.2.4.Market size and forecast, by country
6.2.4.1.U.S. market size and forecast, by product
6.2.4.2.U.S. market size and forecast, by animal type
6.2.4.3.Canada market size and forecast, by product
6.2.4.4.Canada market size and forecast, by animal type
6.2.4.5.Mexico market size and forecast, by product
6.2.4.6.Mexico market size and forecast, by animal type
6.3.Europe
6.3.1.Key market trends, key growth factors and opportunities
6.3.2.Market size and forecast, by product
6.3.3.Market size and forecast, by animal type
6.3.4.Market size and forecast, by country
6.3.4.1.Germany market size and forecast, by product
6.3.4.2.Germany market size and forecast, by animal type
6.3.4.3.France market size and forecast, by product
6.3.4.4.France market size and forecast, by animal type
6.3.4.5.UK market size and forecast, by product
6.3.4.6.UK market size and forecast, by animal type
6.3.4.7.Italy market size and forecast, by product
6.3.4.8.Italy market size and forecast, by animal type
6.3.4.9.Rest of Europe market size and forecast, by product
6.3.4.10.Rest of Europe market size and forecast, by animal type
6.4.Asia-Pacific
6.4.1.Key market trends, key growth factors and opportunities
6.4.2.Market size and forecast, by product
6.4.3.Market size and forecast, by animal type
6.4.4.Market size and forecast, by country
6.4.4.1.Japan market size and forecast, by product
6.4.4.2.Japan market size and forecast, by animal type
6.4.4.3.China market size and forecast, by product
6.4.4.4.China market size and forecast, by animal type
6.4.4.5.Australia market size and forecast, by product
6.4.4.6.Australia market size and forecast, by animal type
6.4.4.7.India market size and forecast, by product
6.4.4.8.India market size and forecast, by animal type
6.4.4.9.South Korea market size and forecast, by product
6.4.4.10.South Korea market size and forecast, by animal type
6.4.4.11.Rest of Asia-Pacific market size and forecast, by product
6.4.4.12.Rest of Asia-Pacific market size and forecast, by animal type
6.5.LAMEA
6.5.1.Key market trends, key growth factors and opportunities
6.5.2.Market size and forecast, by product
6.5.3.Market size and forecast, by animal type
6.5.4.Market size and forecast, by country
6.5.4.1.Brazil market size and forecast, by product
6.5.4.2.Brazil market size and forecast, by animal type
6.5.4.3.Saudi Arabia market size and forecast, by product
6.5.4.4.Saudi Arabia market size and forecast, by animal type
6.5.4.5.Rest of LAMEA market size and forecast, by product
6.5.4.6.Rest of LAMEA market size and forecast, by animal type
CHAPTER 7:COMPANY PROFILES
7.1.ANICON LABOR GMBH
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.2.BOEHRINGER INGELHEIM GMBH
7.2.1.Company overview
7.2.2.Operating business segments
7.2.3.Product portfolio
7.2.4.Business performance
7.2.5.Key strategic moves and developments
7.3.CEVA SANTÉ ANIMALE
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Product portfolio
7.3.4.Key strategic moves and developments
7.4.HYGIEIA BIOLOGICAL LABORATORIES
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.5.MERCK & COMPANY INC.
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.ROMVAC COMPANY S.A.
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.7.SANOFI S.A.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.7.6.Key strategic moves and developments
7.8.VAXXINOVA GMBH
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Key strategic moves and developments
7.9.VIRBAC S.A
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.ZOETIS INC.
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves & developments
LIST OF TABLES
TABLE 01.NUMBER OF U.S. HOUSEHOLDS THAT OWN A PET, BY TYPE OF ANIMAL (MILLION)
TABLE 02.POPULATION OF DOGS AND CATS IN EUROPEAN COUNTRIES, 2019
TABLE 03.MRNA ANIMAL VACCINE: CLINICAL ANALYSIS
TABLE 04.NORTH AMERICA: ANIMAL VACCINES PRICES
TABLE 05.EUROPE: ANIMAL VACCINES PRICES
TABLE 06.ASIA-PACIFIC: ANIMAL VACCINES PRICES
TABLE 07.LAMEA: ANIMAL VACCINES PRICES
TABLE 08.ANIMAL VACCINES MARKET, BY PRODUCT TYPE 2020-2030, ($MILLION)
TABLE 09.ANIMAL VACCINES MARKET FOR ATTENUATED VACCINES BY REGION 2020-2030, ($MILLION)
TABLE 10.ANIMAL VACCINES MARKET FOR INACTIVATED VACCINES BY REGION 2020-2030, ($MILLION)
TABLE 11.ANIMAL VACCINES MARKET FOR SUBUNIT VACCINES BY REGION 2020-2030, ($MILLION)
TABLE 12.ANIMAL VACCINES MARKET FOR TOXOID VACCINES BY REGION 2020-2030, ($MILLION)
TABLE 13.ANIMAL VACCINES MARKET FOR CONJUGATE VACCINES BY REGION 2020-2030, ($MILLION)
TABLE 14.ANIMAL VACCINES MARKET FOR RECOMBINANT VACCINES BY REGION 2020-2030, ($MILLION)
TABLE 15.ANIMAL VACCINES MARKET FOR DNA VACCINES BY REGION 2020-2030, ($MILLION)
TABLE 16.ANIMAL VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 17.COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020-2030, ($MILLION)
TABLE 18.VACCINATION FOR DOGS: CORE AND NON-CORE
TABLE 19.ANIMAL VACCINES MARKET FOR DOGS, BY DISEASE, 2020–2030 ($MILLION)
TABLE 20.VACCINATION FOR CATS: CORE AND NON-CORE
TABLE 21.ANIMAL VACCINES MARKET FOR CATS, BY DISEASE, 2020–2030 ($MILLION)
TABLE 22.COMPANION ANIMAL VACCINES MARKET, BY REGION, 2020-2030, ($MILLION)
TABLE 23.LIVESTOCK ANIMAL VACCINES MARKET, BY TYPE, 2020-2030, ($MILLION)
TABLE 24.ANIMAL VACCINES MARKET FOR CATTLE, BY DISEASE, 2020–2030 ($MILLION)
TABLE 25.TOP 5 PORK CONSUMING COUNTRIES, 2020
TABLE 26.ANIMAL VACCINES MARKET FOR PIGS, BY DISEASE, 2020–2030 ($MILLION)
TABLE 27.TOP 5 POULTRY CONSUMING COUNTRIES, 2020
TABLE 28.ANIMAL VACCINES MARKET FOR POULTRY, BY DISEASE, 2020–2030 ($MILLION)
TABLE 29.TOP 5 SHEEP MEAT CONSUMING COUNTRIES, 2020
TABLE 30.ANIMAL VACCINES MARKET FOR SHEEP, BY DISEASE, 2020–2030 ($MILLION)
TABLE 31.ANIMAL VACCINES MARKET FOR HORSES, BY DISEASE, 2020–2030 ($MILLION)
TABLE 32.LIVESTOCK ANIMAL VACCINES MARKET, BY REGION, 2020-2030, ($MILLION)
TABLE 33.AQUACULTURE ANIMAL VACCINES MARKET, BY REGION, 2020-2030, ($MILLION)
TABLE 34.ANIMAL VACCINES MARKET FOR AQUACULTURE, BY DISEASE, 2020–2030 ($MILLION)
TABLE 35.ANIMAL VACCINES MARKET, BY REGION 2020-2030, ($MILLION)
TABLE 36.NORTH AMERICA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 37.NORTH AMERICA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 38.NORTH AMERICA ANIMAL VACCINES MARKET, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 39.U.S. ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 40.U.S. ANIMAL VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 41.CANADA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 42.CANADA ANIMAL VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 43.MEXICO ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 44.MEXICO VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 45.EUROPE ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 46.EUROPE VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 47.EUROPE ANIMAL VACCINES MARKET, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 48.GERMANY ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 49.GERMANY VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 50.FRANCE ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 51.FRANCE VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 52.UK ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 53.UK VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 54.ITALY ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 55.ITALY VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 56.REST OF EUROPE ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 57.REST OF EUROPE VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 58.ASIA-PACIFIC ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 59.ASIA-PACIFIC VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 60.ASIA-PACIFIC ANIMAL VACCINES MARKET, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 61.JAPAN ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 62.JAPAN VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 63.CHINA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 64.CHINA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 65.AUSTRALIA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 66.AUSTRALIA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 67.INDIA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 68.INDIA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 69.SOUTH KOREA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 70.SOUTH KOREA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 73.LAMEA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 74.LAMEA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 75.LAMEA ANIMAL VACCINES MARKET, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 76.BRAZIL ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 77.BRAZIL VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 78.SAUDI ARABIA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 79.SAUDI ARABIA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 80.REST OF LAMEA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
TABLE 81.REST OF LAMEA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
TABLE 82.ANICON: COMPANY SNAPSHOT
TABLE 83.ANICON: OPERATING SEGMENTS
TABLE 84.ANICON: PRODUCT PORTFOLIO
TABLE 85.BOEHRINGER: COMPANY SNAPSHOT
TABLE 86.BOEHRINGER: OPERATING SEGMENTS
TABLE 87.BOEHRINGER: PRODUCT PORTFOLIO
TABLE 88.CEVA : COMPANY SNAPSHOT
TABLE 89.CEVA : PRODUCT PORTFOLIO
TABLE 90.HYGIEIA: COMPANY SNAPSHOT
TABLE 91.HYGIEIA: OPERATING SEGMENTS:
TABLE 92.HYGIEIA: PRODUCT PORTFOLIO
TABLE 93.MERCK: COMPANY SNAPSHOT
TABLE 94.MERCK: OPERATING SEGMENTS
TABLE 95.MERCK: PRODUCT PORTFOLIO
TABLE 96.ROMVAC: COMPANY SNAPSHOT
TABLE 97.ROMVAC: OPERATING SEGMENTS
TABLE 98.ROMVAC: PRODUCT PORTFOLIO
TABLE 99.SANOFI: COMPANY SNAPSHOT
TABLE 100.SANOFI: OPERATING SEGMENTS
TABLE 101.SANOFI: PRODUCT PORTFOLIO
TABLE 102.VAXXINOVA: COMPANY SNAPSHOT
TABLE 103.VAXXINOVA: OPERATING SEGMENTS
TABLE 104.VAXXINOVA: PRODUCT PORTFOLIO
TABLE 105.VIRBAC: COMPANY SNAPSHOT
TABLE 106.VIRBAC: OPERATING SEGMENTS
TABLE 107.VIRBAC: PRODUCT PORTFOLIO
TABLE 108.ZOETIS: COMPANY SNAPSHOT
TABLE 109.ZOETIS: OPERATING SEGMENTS
TABLE 110.ZOETIS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2018–2021*)
FIGURE 02.TOP WINNING STRATEGIES: BY DEVELOPMENT (2018–2021*)
FIGURE 03.TOP WINNING STRATEGIES: BY COMPANY (2018–2021*)
FIGURE 04.TOP INVESTMENT POCKETS: ANIMAL VACCINES MARKET
FIGURE 05.TOP PLAYER POSITIONING, 2020
FIGURE 06.LOW BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTION
FIGURE 09.MODERATE THREAT OF NEW ENTRANT
FIGURE 10.HIGH COMPETITIVE RIVALRY
FIGURE 11.DRIVERS, RESTRAINTS & OPPORTUNITIES
FIGURE 12.U.S. PET INDUSTRY EXPENDITURE, 2010–2019 ($BILLION)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANIMAL VACCINES MARKET FOR ATTENUATED VACCINES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANIMAL VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ANIMAL VACCINES MARKET FOR SUBUNIT VACCINES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ANIMAL VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ANIMAL VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ANIMAL VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ANIMAL VACCINES MARKET FOR DNA VACCINES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20.TOTAL NUMBER OF PETS OWNED IN THE U.S. (IN MILLIONS)
FIGURE 21.ANIMAL VACCINES MARKET FOR DOGS, 2020–2030 ($MILLION)
FIGURE 22.ANIMAL VACCINES MARKET FOR CATS, 2020–2030 ($MILLION)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF COMPANION ANIMAL VACCINES MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 24.ANIMAL VACCINES MARKET FOR CATTLE, 2020–2030 ($MILLION)
FIGURE 25.ANIMAL VACCINES MARKET FOR PIGS, 2020–2030 ($MILLION)
FIGURE 26.ANIMAL VACCINES MARKET FOR POULTRY, 2020–2030 ($MILLION)
FIGURE 27.ANIMAL VACCINES MARKET FOR SHEEP, 2020–2030 ($MILLION)
FIGURE 28.ANIMAL VACCINES MARKET FOR HORSES, 2020–2030 ($MILLION)
FIGURE 29.ANIMAL VACCINES MARKET FOR OTHERS, 2020–2030 ($MILLION)
FIGURE 30.COMPARATIVE SHARE ANALYSIS OF LIVESTOCK ANIMAL VACCINES MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 31.COMPARATIVE SHARE ANALYSIS OF AQUACULTURE ANIMAL VACCINES MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 32.BOEHRINGER: REVENUE, 2018–2020 ($MILLION)
FIGURE 33.BOEHRINGER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34.BOEHRINGER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 35.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.MERCK: REVENUE SHARE BY PRODUCT, 2020 (%)
FIGURE 37.MERCK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 38.SANOFI: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 40.SANOFI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 41.VIRBAC: REVENUE, 2018–2020 ($MILLION)
FIGURE 42.VIRBAC: REVENUE SHARE BY PRODUCT CATEGORY, 2020 (%)
FIGURE 43.VIRBAC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 44.ZOETIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 45.ZOETIS: REVENUE SHARE BY PRODUCT, 2020 (%)
FIGURE 46.ZOETIS: REVENUE SHARE BY REGION, 2020(%)
The growth in the market is mainly driven by the recent trend of producing vaccines by recombinant DNA technology. The market is dependent on the requirement for animal derived food products such as meat & milk and the need of companion animal for safety of humans and companionship. It is observed that developed countries consume more animal-based food (rather than plant-based foods) as compared to the developing and the underdeveloped countries and spend more on pets due to the higher buying power. With the increase in buying power of developing regions, there would be a need for higher volume of animal-based foods that are expected to drive the growth of the animal vaccines market. Many key players work toward the development of products that are safe for the animals, humans, and surrounding environment.
China, Japan, and Latin America are some of the important countries that majorly contribute toward the market growth due to rise in disposable income, surge in demand for meat in these countries, and increase in adoption of companion animal. Strong bond between the owners and their companion animal and growth in awareness among the owners about these products fuel the growth of the sector. Another key animal type that largely contributes toward the market growth is cattle, owing to the rise in the demand for animal products.
A. The total market value of global animal vaccine Market is $9,093.9 million in 2020
A. The forecast period in the report is from 2021 to 2030
A. The market value of global animal vaccine Market in 2021 was $9,598.3 Million
A. The base year for the report is 2020
A. Yes, global animal vaccine companies are profiled in the report
A. The top companies that hold the market share in global animal vaccine Market are Anicon Labor GmBH, Boehringer Ingelheim GMBH, Ceva Sante Animale, Hygieia Biological Laboratories, Merck & Co., Inc., Romvac Company S.A., Sanofi S.A., Vaxxinova GmbH, Virbac S.A., Zoetis Inc.
A. No, there is no value chain analysis provided in the global animal vaccine Market report
A. The key trends in the global animal vaccine Market are high prevalence of animal diseases among different types of companion and agricultural animals and rise in animal health expenditure
Enterprise
License/PDF
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
